<DOC>
	<DOCNO>NCT00873925</DOCNO>
	<brief_summary>In pilot study investigator try see single intravenous infusion autologous ( self ) cord blood cell follow 1 year daily vitamin D omega 3 fatty acid supplementation preserve beta cell function ( prolong `` honeymoon '' ) child type 1 diabetes . All subject continue use insulin therapy need maintain best possible glucose control . 15 Subjects randomize 2 every 3 ( 10 total ) receive cord blood plus vitamin D Omega 3 1 3 ( 5 total ) serve control receive cord blood , vitamin D , Omega 3 supplementation . The study involve 5 visit 1 year University Florida This study follow-up initial study cord blood infusion alone 23 child receive autologous cord blood . The initial study 100 % safe additional study like one described need determine improve cord blood base therapy .</brief_summary>
	<brief_title>Cord Blood Plus Vitamin D Omega 3 T1D</brief_title>
	<detailed_description>Hypothesis : We hypothesize combination intensive insulin therapy , autologous umbilical cord blood ( UCB ) , Vitamin D , Omega 3 fatty acid administer child T1D preserve residual c-peptide compare child receive intensive insulin therapy alone Specific Aims : 1 . Randomize 15 child recent onset T1D available autologous cord blood 10 receive combination intensive insulin therapy , autologous UCB infusion , daily Vitamin D 5 receive intensive insulin therapy alone 2 . Document safety combination therapy 3 . Study potential change glucose metabolism 4 . Study potential change immune function Preliminary Studies : Our group already perform autologous cord blood infusion 23 child T1D document safety approach . While conclusive data regard efficacy infusion preserve beta cell function lacking , pilot study demonstrate potential cord blood low rate c-peptide decline ( measure beta cell function/mass ) young child T1D . As documented , considerable work institution suggest potential combination Vitamin D DHA augment autoimmune response . Given safety potential efficacy approach , feel pilot study combination UCB infusion , vitamin D supplementation , DHA supplementation warrant . Screening : Only subject still make least small amount detectable insulin eligible study . To determine child still make insulin , undergo mixed meal tolerance test . This involve place IV morning prior eat . The subject drink `` mixed meal '' ( nutritional supplement Boost use ) blood take via IV timepoints next 2 hour determine insulin still produce . Randomization : If potential subject `` pass '' screen test , randomize either receive study intervention control . Subjects WILL tell arm study randomize . Infusion : Those randomized infusion return University Florida single autologous cord blood infusion give vitamin D Omega 3 supplement Follow-up : Both Control Intervention subject return 3 , 6 , 12 month infusion/screening visit blood drawn repeat mixed meal tolerance test , measurement HbA1c , immune study .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>TID diagnosis confirm presence least 1 diabetes autoantibody Children â‰¥ 1 year Stored autologous umbilical cord blood ( 15 seek ) AABB and/or FACT accredit cord bank . Stimulated Cpeptide &gt; 0.2pmol/L MMTT Cord blood meet selection test criterion ( see ) . Normal screen value CBC , Renal function electrolyte ( BMP Ca , Mg , Phos ) . Willing comply intensive diabetes management Complicating medical issue would interfere blood draw monitoring . Chronic use steroid immunosuppressive agent condition . Positive infectious disease marker mother 's blood cord time collection ( See detail ) . Any evidence illness plan infusion date ( i.e . fever &gt; 38.5 C , vomit , diarrhea , wheeze , crackle ) . Allergy DHA ( Omega 3 ) Vitamin D Hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Type 1 Diabetes</keyword>
</DOC>